RxDoctor Payments Data

William Behrens, MD

Family Medicine · Annapolis, MDNPI 1841291564

Payments from drug & device makers

$1,942in general payments, 2019–2025

Across 96 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$533
  • Pfizer$180
  • Amgen$180
  • Abbott$179
  • Novo Nordisk$158
  • Exact Sciences$113
  • plus $599 from 16 others

What the payments were for

  • Food & beverage$1,942100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,942 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$255,611
Medicare patients
473
Services billed
7,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$104,361
JardianceEmpagliflozin53$77,232
TrulicityDulaglutide29$38,074
JanuviaSitagliptin Phosphate23$34,324
EliquisApixaban31$33,468
XareltoRivaroxaban20$27,253
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,688
MounjaroTirzepatide16$18,405
Rosuvastatin Calcium354$9,474
Pravastatin Sodium265$6,952
Losartan Potassium355$5,392
SynthroidLevothyroxine Sodium49$4,599
Advair HfaFluticasone Propion/Salmeterol11$3,388
Metoprolol Succinate148$3,346
Atorvastatin Calcium229$3,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$158$104,36168 claims
Boehringer IngelheimJardiance$62$77,23253 claims
Lilly USA, LLCTrulicity, Mounjaro$21$56,47945 claims
PfizerEliquis, Paxlovid$180$34,89742 claims
MerckJanuvia$29$34,32423 claims
Johnson & JohnsonXarelto$63$27,25320 claims
GSKTrelegy Ellipta$99$18,68826 claims
AbbVieSynthroid$533$4,59949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →